Radar signals

PASS CRBG · 16 hours ago · votes buy:0 pass:3

Nippon Life Insurance Co., a 10% owner of Corebridge Financial, disclosed an $8.8 million CRBG stock purchase. The trade fell short mainly because this buyer has no verified history of outperforming SPY, so the signal is unproven despite its size and prompt disclosure. A verified record of successful prior purchases, especially if supported by other recent insider buyers, could have changed the verdict.

PASS CXM · 16 hours ago · votes buy:1 pass:2

Sprinklr director Stephen M. Ward Jr. disclosed buying about $850,500 of CXM stock. The panel passed mainly because he has no verified trading history versus SPY, so this large purchase remains an unproven signal. A record of his prior purchases outperforming SPY would have provided the strongest evidence to change the verdict.

PASS ASB · 16 hours ago · votes buy:0 pass:3

Associated Banc-Corp General Counsel Angela Kelley disclosed about $500,000 in ASB shares. The panel passed because available reporting describes them as sign-on shares that vest over time, so the transaction may be compensation rather than a discretionary open-market buy. An official Form 4 confirming transaction code “P” and that Kelley used her own funds would have strengthened the case; her lack of a verified trading record remains the main caveat.

PASS BEN · 18 hours ago · votes buy:0 pass:3

Franklin Resources co-president Daniel Gamba disclosed a roughly $2.56 million purchase of BEN, joining several other company insiders who recently bought shares. The panel passed mainly because Gamba has no verified trading history, so his purchase is not yet a proven signal despite its size and the insider cluster. A documented record showing that his earlier open-market buys consistently outperformed SPY would have strengthened the case enough to reconsider the verdict.

PASS BEN · 18 hours ago · votes buy:0 pass:3

Franklin Resources officer Terrence Murphy was reported as buying about $4.29 million of BEN stock. The panel passed mainly because the listed October 2026 trade date is in the future, so the purchase could not be verified as a completed insider buy despite activity from several other insiders. A matching SEC Form 4 confirming the date, share count, price, and open-market purchase would have addressed the main concern.

PASS BRK-A · 21 hours ago · votes buy:0 pass:3

Rep. Rich McCormick disclosed a $1,001–$15,000 purchase listed as BRK-A, with two other tracked buyers appearing within 45 days. The panel passed mainly because the reported maximum is far below the price of one BRK-A share, creating doubt about whether the ticker or transaction details are correct. A filing excerpt confirming BRK-A and documenting a fractional-share purchase or the exact amount would have addressed the key concern.

PASS BPRE · 2 days ago · votes buy:0 pass:3

BPRE director Ramin Kamfar disclosed buying about $2.06 million of stock, while another tracked insider also bought recently. The panel passed mainly because Kamfar has no verified trading history, so the purchase is not yet a proven signal. A verified record showing that his prior purchases consistently outperformed SPY would have strengthened the case; the future-dated trade should also be confirmed against the underlying Form 4.

PASS AKTX · 2 days ago · votes buy:0 pass:3

Akari Therapeutics Chief Business Officer Vat-Ho Vatnak disclosed an AKTX purchase of about $777,780, alongside another recent insider buyer. The trade fell short mainly because Vatnak has no verified trading history, so there is no evidence that his prior buys have outperformed SPY. A verified record of strong performance after several comparable open-market purchases would have supported a different verdict.

PASS UTHR · 2 days ago · votes buy:0 pass:3

United Therapeutics Chairperson and CEO Martine Rothblatt was reported as buying about $1.12 million of UTHR stock. The panel passed because the transaction may be misclassified: a news report describes the same 9,500 shares and $117.76 price as an option exercise followed by a sale, while the trade date also requires verification. A confirmed SEC filing showing a true open-market purchase would have materially strengthened the case and could have changed the verdict.

PASS ECF · 2 days ago · votes buy:0 pass:3

Saba Capital Management, a 10% owner of ECF, disclosed buying about $175,638 of shares. The trade fell short mainly because Saba has no verified record of beating SPY, so its buyer signal remains unproven. A documented history of strong risk-adjusted returns on similar disclosed purchases would have been the clearest evidence to change the verdict; the lack of other recent tracked buyers is an added caveat.

PASS AFRM · 2 days ago · votes buy:0 pass:3

Affirm CFO Robert O’Hare disclosed a roughly $324,577 stock purchase, joining another company officer who recently bought AFRM. The panel passed mainly because O’Hare has no verified trading history, so the insider signal is unproven despite the purchase size and cluster. A meaningful, verified record showing his past open-market buys outperforming SPY would have supported a different verdict.

PASS AFRM · 2 days ago · votes buy:0 pass:3

Affirm CFO Robert O’Hare reportedly bought about $396,143 of AFRM stock, joining another company officer who recently bought shares. The panel passed mainly because the reported trade and disclosure dates are future-dated, so the purchase cannot yet be reliably verified. A valid SEC filing confirming the open-market purchase and corrected dates could have changed the verdict.

PASS AFRM · 2 days ago · votes buy:0 pass:3

Affirm CFO Robert O’Hare reportedly bought about $228,330 of AFRM stock, joining another company officer who recently bought shares. The panel passed mainly because the trade is future-dated and lacks a supporting source excerpt, so the purchase could not be reliably verified. An official SEC Form 4 confirming the date, price, share count, and open-market nature of the purchase would have strengthened the case enough to reconsider it, though O’Hare’s track record remains unproven.

PASS AFRM · 2 days ago · votes buy:0 pass:3

Affirm CFO Robert O’Hare reportedly bought about $292,625 of AFRM stock, while another company officer also bought shares within 45 days. The panel passed mainly because O’Hare has no verified trading history, so the insider signal is unproven despite the sizable purchase. A verified record showing that his prior buys consistently outperformed the S&P 500 would have strengthened the case enough to change the verdict.

PASS NUCL · 2 days ago · votes buy:0 pass:3

NUCL director Jeffrey Herschel reportedly bought 12,500 shares for about $75,625, joining three other recent insider buyers. The panel passed mainly because the trade and disclosure dates are future-dated and no underlying SEC Form 4 was provided, so the purchase could not be verified. A filed Form 4 confirming an open-market purchase, price, and dates would have materially changed the verdict.